Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 810
- Registration Number
- NCT05519085
- Locations
- 🇺🇸
Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
- Conditions
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 42
- Registration Number
- NCT05514990
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Los Angeles County-USC Medical Center, Los Angeles, California, United States
PVd Versus Vd in NDMM Patients With RI
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 79
- Registration Number
- NCT05432414
- Locations
- 🇨🇳
Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Xia Zhongjun
- Target Recruit Count
- 42
- Registration Number
- NCT05422027
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China,, Guangzhou, Guangdong, China
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
- Conditions
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT05392946
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Bortezomib for Treating Glomerular Diseases
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05383547
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05293509
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
High-Dose Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Following Allogenic Hematopoietic Stem Cell Transplantation (HSCT) Study
- Conditions
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 74
- Registration Number
- NCT05289167
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
- Conditions
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 75
- Registration Number
- NCT05272826
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 750
- Registration Number
- NCT05257083
- Locations
- 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UC San Diego Health Moores Cancer Center, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.